AbSci (ABSI)

Executive Summary

AbSci is a clinical-stage generative AI drug creation company pioneering a new approach to biologics discovery. By integrating high-throughput synthetic biology with deep learning AI, its platform aims to design novel antibodies and other biologics from scratch against challenging targets, with the goal of accelerating the path to better medicines for patients. The company's lead program, ABS-201, is currently in a Phase 1/2 clinical trial for androgenetic alopecia (AGA). The trial (NCT07317544) began recruiting in December 2025 and is expected to complete by July 2028. AbSci's technology platform has the potential to dramatically reduce drug development timelines and unlock previously undruggable targets. As a public company (NASDAQ: ABSI) with a market capitalization of approximately $870 million, AbSci represents an early-stage investment opportunity in the rapidly evolving field of AI-driven drug discovery. The company has not yet received any FDA approvals but continues to advance its pipeline and expand its platform capabilities.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 Interim Data for ABS-201 in AGA40% success
• TBDPharma Collaboration or Platform License Deal30% success
• Q4 2026Next Pipeline Candidate Nomination or IND Filing50% success